Novobismol, 120 mg 56 pcs.

Novobismol is an anti-ulcer agent with bactericidal activity against Helicobacter pylori.

It also has anti-inflammatory and astringent action.

In the acidic environment of the stomach it forms insoluble bismuth oxychloride and citrate and also forms chelated compounds with protein substrate in the form of a protective film on the surface of ulcers and erosions.

With increased synthesis of prostaglandin E, mucus formation and hydrocarbonate secretion, it stimulates the activity of cytoprotective mechanisms and increases resistance of gastrointestinal mucosa to pepsin, hydrochloric (hydrochloric) acid, enzymes and bile salts.

Leads to the accumulation of epidermal growth factor in the defect area.

Reduces the activity of pepsin and pepsinogen.

Indications

Gastric and duodenal ulcer in the acute phase (including one associated with Helicobacter pylori;

Active ingredient

Composition

Active substances:

Bismuth tricalium dicitrate 304.6 mg, which corresponds to the content of bismuth oxide 120 mg;

Auxiliary substances:

Corn starch – 70.6 mg,

Povidone K 30 – 17.7 mg,

potassium polyacrylate – 23.6 mg,

macrogol 6000 – 6.0 mg,

magnesium stearate – 2.0 mg

How to take, the dosage

Adults and children over 4 years of age – orally 2-4 times a day 30 min before meals. The dose of Novobismol depends on the patient’s age.

The course of treatment is 4-8 weeks. For the next 8 weeks, you should not take medications containing bismuth.

For eradication of Helicobacter pylori it is reasonable to use bismuth tricalium dicitrate in combination with antibacterial drugs that have anti-Helicobacterial activity.

Interaction

The simultaneous use of other drugs, as well as food and liquids, particularly antacids, milk, fruit and fruit juices may change the effectiveness of bismuth tricalium dicitrate.

Special Instructions

Novobismol should not be used for more than 8 weeks.

It is not recommended to exceed the established daily doses for adults and children during treatment.

At the end of the course of treatment at the recommended doses, plasma concentrations of the active ingredient do not exceed 3-58 µg/L, and intoxication is observed only at concentrations greater than 100 µg/L.

Bismuth sulfide may cause stool coloring in black against the background of use.

Sometimes a slight darkening of the tongue is noted.

Contraindications

Developed renal dysfunction, pregnancy, lactation, hypersensitivity to bismuth tricalium dicitrate.

Side effects

Gastrointestinal tract disorders: nausea, vomiting, increased stool frequency, constipation.

Allergic reactions: skin rash, itching.

Others: in prolonged use in high doses – encephalopathy associated with the accumulation of bismuth in the CNS.

Pregnancy use

It is contraindicated in pregnancy and during lactation (breastfeeding).

Similarities